Develops treatments for metabolic disorders and Alzheimer's disease.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company headquartered in High Point, North Carolina, specializes in developing oral treatments for diabetes and other chronic diseases. Central to its pipeline is TTP399, a liver-selective glucokinase activator designed for type 1 diabetes. Additionally, the company is advancing HPP737, an oral PDE4 inhibitor targeting inflammatory conditions like psoriasis. Beyond diabetes, vTv Therapeutics Inc. is actively exploring TTP273, a GLP-1 receptor agonist aimed at managing postprandial glucose levels in cystic fibrosis-related diabetes.
The company's diverse portfolio includes HPP3033, a novel therapy leveraging the Nrf2 pathway to address chronic diseases associated with oxidative stress. Moreover, vTv Therapeutics Inc. is developing azeliragon, a RAGE antagonist with potential applications in severe COVID-19 and various cancers, such as pancreatic and breast cancer. Collaborating with pharmaceutical partners, the company also pursues HPP971, an Nrf2 activator focused on renal diseases. Through strategic partnerships, including with Reneo Pharmaceuticals, Inc., vTv Therapeutics Inc. expands its capabilities in developing therapeutic programs like HPP593, a peroxisome proliferation activated receptor delta agonist.
Established in 2015 as a subsidiary of MacAndrews & Forbes Incorporated, vTv Therapeutics Inc. has cultivated a robust network of collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Committed to innovation in biopharmaceuticals, vTv Therapeutics Inc. aims to advance treatments that enhance the quality of life for patients worldwide.